FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022677075> ?p ?o ?g. }

• W2022677075 endingPage "n/a" @default.
• W2022677075 startingPage "n/a" @default.
• W2022677075 abstract "We have read with interest the comments provided by Lodé et al (2013) regarding our findings of a correlation of cereblon (CRBN) expression and response in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Heintel et al, 2013). We agree that the prime time has not yet arrived for the routine use of CRBN expression as treatment guidance. Lodé et al (2013) raise three important issues that should be evaluated before drawing final conclusions and we wish to add the following: In relation to the first point raised, we suggest that CRBN should be analysed in both the CD138+ and CD138− fraction of MM bone marrow samples in future studies. It is well recognized that at least some of the effect of immunomodulatory drugs (IMiDs) is mediated through the microenvironment by induction of proliferation of T-cells and other effector cells, of expression of co-stimulatory molecules and modification of cytokine signalling (Görgün et al, 2010), resulting in an anti-myeloma immune response. Lopez-Girona et al (2012) showed that CRBN not only mediates the anti-proliferative effects of lenalidomide and pomalidomide in myeloma cells, but also lenalidomide- and pomalidomide -induced cytokine production in T-cells. In our paper we provided data showing that, although median CRBN expression is lower in the CD138− than CD138+ fraction, expression levels of CRBN vary in the MM bone marrow environment and can be considerably higher than in normal bone marrow (Heintel et al, 2013). Thus we speculate that variable levels of CRBN in immune cells in the bone marrow might have contributed to the association with response in our study. We fully agree with the second point raised, that CRBN physiology needs to be studied in detail and the function of the different isoforms elucidated. Lenalidomide treatment was shown to induce 2-fold expression changes in approximately 1200 genes, and the vast majority of these changes seem to be mediated via CRBN (Zhu et al, 2011). Lodé et al (2013) provide important data showing the frequent occurrence of alternative transcripts, accounting in some patients for >50% of total CRBN in some patients. It has been reported that CRBN downregulation mediates resistance to IMiD-based treatment (Zhu et al, 2011; Heintel et al, 2013). As preferential expression of transcripts lacking a functional IMiD binding domain would be anticipated to have a similar effect, we propose studying the expression of alternative transcripts of CRBN with regard to primary resistance and acquisition of resistance to IMiD based treatment. Gandhi et al (2012) reported on an antibody (CRBN65) capable of discriminating the different isoforms by Western blot, and such a tool should be helpful in these studies. In contrast, truncating mutations in CRBN seem to be a rare mechanism of acquisition of resistance (Egan et al, 2013). Once the correlation between CRBN expression and clinical response can be corroborated, antibodies binding to CRBN or its isoforms might provide the basis for developing a reliable routine test for CRBN expression. Developing a flow cytometric technique for detection might provide further insight into intra-tumour heterogeneity of CRBN expression. It should be noted that three other groups have already reported a correlation between CRBN expression and outcome under IMiD therapy, one using tissue microarrays and fluorescence immunohistochemistry to quantify CRBN expression (Klimowicz et al, 2012), the two other groups using gene expression profiling (Broyl et al, 2013; Schuster et al, 2012). The in-silico analysis performed by Lodé et al (2013) provides important insights with regard to CRBN expression in the different molecular MM subgroups. While median CRBN expression is higher in the hyperdiploid subgroup, there seems to be great variability of expression within all subgroups. In our preliminary analysis we could not find a correlation between CRBN expression and fluorescent in situ hybridization-defined high-risk or standard risk disease. We did not study chromosome 3 trisomy in our series of patients but agree that cytogenetic data should be evaluated in relation to CRBN expression. We think that the outcome defined by response is less biased by a possible overweight of hyperdiploid disease, as the main impact of the molecular signature is on survival parameters, not initial response to therapy. A very rapid and deep response to therapy, with regard to serum free-light chain levels, might even identify a subgroup of patients with inferior survival. It should be noted that the groups who have reported a correlation between CRBN expression and outcome with IMiD-based treatment defined by survival have included a bortezomib-treated control group, where this association was lacking (Broyl et al, 2013; Klimowicz et al, 2012), thus making a bias related to a possible prognostic significance of CRBN expression itself less likely." @default.
• W2022677075 created "2016-06-24" @default.
• W2022677075 creator A5014914114 @default.
• W2022677075 creator A5028662013 @default.
• W2022677075 creator A5059967673 @default.
• W2022677075 creator A5069042392 @default.
• W2022677075 date "2013-07-01" @default.
• W2022677075 modified "2023-09-23" @default.
• W2022677075 title "Cereblon expression in multiple myeloma: not ready for prime time - Response to Lodéet al" @default.
• W2022677075 cites W1965604161 @default.
• W2022677075 cites W1969572138 @default.
• W2022677075 cites W1977943803 @default.
• W2022677075 cites W2000047150 @default.
• W2022677075 cites W2025656486 @default.
• W2022677075 cites W2049005444 @default.
• W2022677075 cites W2066713758 @default.
• W2022677075 doi "https://doi.org/10.1111/bjh.12477" @default.
• W2022677075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23869521" @default.
• W2022677075 hasPublicationYear "2013" @default.
• W2022677075 type Work @default.
• W2022677075 sameAs 2022677075 @default.
• W2022677075 citedByCount "2" @default.
• W2022677075 countsByYear W20226770752014 @default.
• W2022677075 countsByYear W20226770752021 @default.
• W2022677075 crossrefType "journal-article" @default.
• W2022677075 hasAuthorship W2022677075A5014914114 @default.
• W2022677075 hasAuthorship W2022677075A5028662013 @default.
• W2022677075 hasAuthorship W2022677075A5059967673 @default.
• W2022677075 hasAuthorship W2022677075A5069042392 @default.
• W2022677075 hasBestOaLocation W20226770751 @default.
• W2022677075 hasConcept C104317684 @default.
• W2022677075 hasConcept C109159458 @default.
• W2022677075 hasConcept C134459356 @default.
• W2022677075 hasConcept C203014093 @default.
• W2022677075 hasConcept C25602115 @default.
• W2022677075 hasConcept C2776063141 @default.
• W2022677075 hasConcept C2776364478 @default.
• W2022677075 hasConcept C2778524551 @default.
• W2022677075 hasConcept C2778540781 @default.
• W2022677075 hasConcept C2778690821 @default.
• W2022677075 hasConcept C2780007613 @default.
• W2022677075 hasConcept C28328180 @default.
• W2022677075 hasConcept C502942594 @default.
• W2022677075 hasConcept C55493867 @default.
• W2022677075 hasConcept C71924100 @default.
• W2022677075 hasConcept C86803240 @default.
• W2022677075 hasConcept C8891405 @default.
• W2022677075 hasConcept C95444343 @default.
• W2022677075 hasConceptScore W2022677075C104317684 @default.
• W2022677075 hasConceptScore W2022677075C109159458 @default.
• W2022677075 hasConceptScore W2022677075C134459356 @default.
• W2022677075 hasConceptScore W2022677075C203014093 @default.
• W2022677075 hasConceptScore W2022677075C25602115 @default.
• W2022677075 hasConceptScore W2022677075C2776063141 @default.
• W2022677075 hasConceptScore W2022677075C2776364478 @default.
• W2022677075 hasConceptScore W2022677075C2778524551 @default.
• W2022677075 hasConceptScore W2022677075C2778540781 @default.
• W2022677075 hasConceptScore W2022677075C2778690821 @default.
• W2022677075 hasConceptScore W2022677075C2780007613 @default.
• W2022677075 hasConceptScore W2022677075C28328180 @default.
• W2022677075 hasConceptScore W2022677075C502942594 @default.
• W2022677075 hasConceptScore W2022677075C55493867 @default.
• W2022677075 hasConceptScore W2022677075C71924100 @default.
• W2022677075 hasConceptScore W2022677075C86803240 @default.
• W2022677075 hasConceptScore W2022677075C8891405 @default.
• W2022677075 hasConceptScore W2022677075C95444343 @default.
• W2022677075 hasLocation W20226770751 @default.
• W2022677075 hasLocation W20226770752 @default.
• W2022677075 hasOpenAccess W2022677075 @default.
• W2022677075 hasPrimaryLocation W20226770751 @default.
• W2022677075 hasRelatedWork W2029049499 @default.
• W2022677075 hasRelatedWork W2030475312 @default.
• W2022677075 hasRelatedWork W2152391690 @default.
• W2022677075 hasRelatedWork W2514979620 @default.
• W2022677075 hasRelatedWork W2556714189 @default.
• W2022677075 hasRelatedWork W2952246870 @default.
• W2022677075 hasRelatedWork W3010457103 @default.
• W2022677075 hasRelatedWork W3012478396 @default.
• W2022677075 hasRelatedWork W3103983965 @default.
• W2022677075 hasRelatedWork W4283724058 @default.
• W2022677075 isParatext "false" @default.
• W2022677075 isRetracted "false" @default.
• W2022677075 magId "2022677075" @default.
• W2022677075 workType "article" @default.